Effects of Spirulina supplementation on obesity: A systematic review and meta-analysis of randomized clinical trials

Complementary Therapies in Medicine

Volumn 47, Issue , 2019, Pages

  Moradi, Sajjad ^a,b   Ziaei, Rahele ^c   Foshati, Sahar ^c   Mohammadi, Hamed ^d   Nachvak, Seyed Mostafa ^b   Rouhani, Mohammad Hossein ^c  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b KERMANSHAH UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^c ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

^d ISFAHAN UNIVERSITY OF MEDICAL SCIENCES   (Iran)

Author keywords

Meta analysis; Obesity; Spirulina; Systematic review

Indexed keywords

ADULT; BODY FAT; BODY MASS; BODY WEIGHT CHANGE; COCHRANE LIBRARY; EMBASE; FEMALE; HEALTH STATUS; HUMAN; MALE; MEDLINE; META ANALYSIS; NONHUMAN; OBESE PATIENT; PUBLICATION BIAS; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SCOPUS; SENSITIVITY ANALYSIS; SPIRULINA; SYSTEMATIC REVIEW; WAIST CIRCUMFERENCE; WAIST HIP RATIO; WEB OF SCIENCE; ANTHROPOMETRY; BODY WEIGHT LOSS; DIETARY SUPPLEMENT; OBESITY;

ANTHROPOMETRY; DIETARY SUPPLEMENTS; HUMANS; OBESITY; RANDOMIZED CONTROLLED TRIALS AS TOPIC; SPIRULINA; WEIGHT LOSS;

EID: 85073740261     PISSN: 09652299     EISSN: 18736963     Source Type: Journal    
DOI: 10.1016/j.ctim.2019.102211     Document Type: Review

References (58)

1. World Health Organization, Obesity and overweight. 2018 Accessed 2018-12-19 https://www.who.int/news-room/fact-sheets/detail/obesity-and-overweight.
2. Ezzati, M., Riboli, E., Behavioral and dietary risk factors for noncommunicable diseases. N Engl J Med 369 (2013), 954–964.
3. Moradi, S., Mirzaei, K., Abdurahman, A.A., Keshavarz, S.A., Hossein-nezhad, A., Mediatory effect of circulating vaspin on resting metabolic rate in obese individuals. Eur J Nutr 55:3 (2016), 1297–1305.
4. Lee, C.M.Y., Huxley, R.R., Wildman, R.P., Woodward, M., Indices of abdominal obesity are better discriminators of cardiovascular risk factors than BMI: a meta-analysis. J Clin Epidemiol 61 (2008), 646–653.
5. Romero-Corral, A., Somers, V.K., Sierra-Johnson, J., et al. Normal weight obesity: a risk factor for cardiometabolic dysregulation and cardiovascular mortality. Eur Heart J 31 (2010), 737–746.
6. Oliveros, E., Somers, V.K., Sochor, O., Goel, K., Lopez-Jimenez, F., The concept of normal weight obesity. Prog Cardiovasc Dis 56 (2014), 426–433.
7. Rios-Hoyo, A., Gutierrez-Salmean, G., New dietary supplements for obesity: what we currently know. Curr Obes Rep 5:2 (2016), 262–270.
8. Vesely, J.M., DeMattia, L.G., Obesity: drugs and dietary supplements. FP Essent 425 (2014), 16–23.
9. Kang, J.G., Park, C.-Y., Anti-obesity drugs: a review about their effects and safety. Diabetes Metab J 36:1 (2012), 13–25.
10. Cicero, A.F.G., Colletti, A., Role of phytochemicals in the management of metabolic syndrome. Phytomedicine 23:11 (2016), 1134–1144.
11. Rivellese, A.A., Ciciola, P., Costabile, G., Vetrani, C., Vitale, M., The possible role of nutraceuticals in the prevention of cardiovascular disease. High Blood Press Cardiovasc Prev 26:2 (2019), 101–111.
12. Patti, A.M., Al-Rasadi, K., Giglio, R.V., et al. Natural approaches in metabolic syndrome management. Arch Med Sci 14:2 (2018), 422–441.
13. Kulshreshtha, A., Jarouliya, U., Bhadauriya, P., Prasad, G., Bisen, P., Spirulina in health care management. Curr Pharm Biotechnol 9:5 (2008), 400–405.
14. Yousefi, R., Saidpour, A., Mottaghi, A., The effects of Spirulina supplementation on metabolic syndrome components, its liver manifestation and related inflammatory markers: a systematic review. Complement Ther Med 42 (2018), 137–144.
15. Wu, Q., Liu, L., Miron, A., Klímová, B., Wan, D., Kuča, K., The antioxidant, immunomodulatory, and anti-inflammatory activities of Spirulina: an overview. Arch Toxicol 90 (2016), 1817–1840.
16. Abebe, W., Agrawal, D.K., Role of tyrosine kinases in norepinephrine-induced contraction of vascular smooth muscle. J Cardiovasc Pharmacol 26:1 (1995), 153–159.
17. Finamore, A., Palmery, M., Bensehaila, S., Peluso, I., Antioxidant, immunomodulating, and microbial-modulating activities of the sustainable and ecofriendly Spirulina. Oxid Med Cell Longev, 2017, 2017, 3247528.
18. Karczewski, J., Sledzinska, E., Baturo, A., et al. Obesity and inflammation. Eur Cytokine Netw 29:3 (2018), 83–94.
19. Yousefi, R., Mottaghi, A., Saidpour, A., Spirulina platensis effectively ameliorates anthropometric measurements and obesity-related metabolic disorders in obese or overweight healthy individuals: a randomized controlled trial. Complement Ther Med 40 (2018), 106–112.
20. Ramamoorthy, A., Premakumari, S., Effect of supplementation of Spirulina on hypercholesterolemic patients. J Food Sci Technol (Mysore) 33 (1996), 124–128.
21. Lee, E.H., Park, J.-E., Choi, Y.-J., Huh, K.-B., Kim, W.-Y., A randomized study to establish the effects of Spirulina in type 2 diabetes mellitus patients. Nutr Res Pract 2 (2008), 295–300.
22. Mazokopakis, E.E., Starakis, I.K., Papadomanolaki, M.G., Mavroeidi, N.G., Ganotakis, E.S., The hypolipidaemic effects of Spirulina (Arthrospira platensis) supplementation in a Cretan population: a prospective study. J Sci Food Agric 94 (2014), 432–437.
23. Miczke, A., Szulińska, M., Hansdorfer-Korzon, R., et al. Effects of Spirulina consumption on body weight, blood pressure, and endothelial function in overweight hypertensive Caucasians: a double-blind, placebo-controlled, randomized trial. Eur Rev Med Pharmacol Sci 20 (2016), 150–156.
24. Zeinalian, R., Farhangi, M.A., Shariat, A., Saghafi-Asl, M., The effects of Spirulina platensis on anthropometric indices, appetite, lipid profile and serum vascular endothelial growth factor (VEGF) in obese individuals: a randomized double blinded placebo controlled trial. BMC Complement Altern Med, 17, 2017, 225.
25. Szulinska, M., Gibas-Dorna, M., Miller-Kasprzak, E., et al. Spirulina maxima improves insulin sensitivity, lipid profile, and total antioxidant status in obese patients with well-treated hypertension: a randomized double-blind placebo-controlled study. Eur Rev Med Pharmacol Sci 21 (2017), 2473–2481.
26. Hernández-Lepe, M., López-Díaz, J., Juárez-Oropeza, M., Hernández-Torres, R., Wall-Medrano, A., Ramos-Jiménez, A., Effect of Arthrospira (Spirulina) maxima supplementation and a systematic physical exercise program on the body composition and cardiorespiratory fitness of overweight or obese subjects: a double-blind, randomized, and crossover controlled trial. Mar Drugs, 16, 2018, E364.
27. Higgins, J.P., Altman, D.G., Gøtzsche, P.C., et al. The Cochrane Collaboration's tool for assessing risk of bias in randomised trials. Bmj, 343, 2011, d5928.
28. Begg, C.B., Mazumdar, M., Operating characteristics of a rank correlation test for publication bias. Biometrics, 1994, 1088–1101.
29. Egger, M., Smith, G.D., Schneider, M., Minder, C., Bias in meta-analysis detected by a simple, graphical test. Bmj 315:7109 (1997), 629–634.
30. Mazokopakis, E.E., Starakis, I.K., Papadomanolaki, M.G., Mavroeidi, N.G., Ganotakis, E.S., The hypolipidaemic effects of Spirulina (Arthrospira platensis) supplementation in a Cretan population: a prospective study. J Sci Food Agric 94:3 (2014), 432–437.
31. Masuda, K., Chitundu, M., Multiple micronutrient supplementation using spirulina platensis and infant growth, morbidity and motor development: evidence from a randomized trial in Zambia. 2018.
32. Samuels, R., Mani, U., Iyer, U., Nayak, U., Hypocholesterolemic effect of Spirulina in patients with hyperlipidemic nephrotic syndrome. J Med Food 5:2 (2002), 91–96.
33. Ramamoorthy, A., Premakumari, S., Effect of supplementation of Spirulina on hypercholesterolemic patients. J Food Sci Technol 33:2 (1996), 124–128.
34. Szulinska, M., Gibas-Dorna, M., Miller-Kasprzak, E., et al. Spirulina maxima improves insulin sensitivity, lipid profile, and total antioxidant status in obese patients with well-treated hypertension: a randomized double-blind placebo-controlled study. Eur Rev Med Pharmacol Sci 21:10 (2017), 2473–2481.
35. Hernández-Lepe, M., López-Díaz, J., Juárez-Oropeza, M., Hernández-Torres, R., Wall-Medrano, A., Ramos-Jiménez, A., Effect of Arthrospira (Spirulina) maxima supplementation and a systematic physical exercise program on the body composition and cardiorespiratory fitness of overweight or obese subjects: a double-blind, randomized, and crossover controlled trial. Mar Drugs, 16(10), 2018, 364.
36. Zeinalian, R., Farhangi, M.A., Shariat, A., Saghafi-Asl, M., The effects of Spirulina Platensis on anthropometric indices, appetite, lipid profile and serum vascular endothelial growth factor (VEGF) in obese individuals: a randomized double blinded placebo controlled trial. BMC Complement Altern Med, 17(1), 2017, 225.
37. Fujimoto, M., Tsuneyama, K., Fujimoto, T., Selmi, C., Gershwin, M.E., Shimada, Y., Spirulina improves non-alcoholic steatohepatitis, visceral fat macrophage aggregation, and serum leptin in a mouse model of metabolic syndrome. Dig Liver Dis 44:9 (2012), 767–774.
38. Wu, Q., Liu, L., Miron, A., Klimova, B., Wan, D., Kuca, K., The antioxidant, immunomodulatory, and anti-inflammatory activities of Spirulina: an overview. Arch Toxicol 90:8 (2016), 1817–1840.
39. Yousefi, R., Mottaghi, A., Saidpour, A., Spirulina platensis effectively ameliorates anthropometric measurements and obesity-related metabolic disorders in obese or overweight healthy individuals: a randomized controlled trial. Complement Ther Med 40 (2018), 106–112.
40. Nasirian, F., Dadkhah, M., Moradi-Kor, N., Obeidavi, Z., Effects of Spirulina platensis microalgae on antioxidant and anti-inflammatory factors in diabetic rats. Diabetes Metab Syndr Obes 11 (2018), 375–380.
41. Park, W.S., Kim, H.J., Li, M., et al. Two classes of pigments, carotenoids and C-phycocyanin, in Spirulina powder and their antioxidant activities. Molecules (Basel, Switzerland), 23(8), 2018.
42. Liu, Q., Huang, Y., Zhang, R., Cai, T., Cai, Y., Medical application of Spirulina platensis derived C-phycocyanin. Evid Based Complement Altern Med, 2016, 2016, 7803846.
43. Deng, R., Chow, T.J., Hypolipidemic, antioxidant, and antiinflammatory activities of microalgae Spirulina. Cardiovasc Ther 28:4 (2010), e33–45.
44. Sadek, K.M., Lebda, M.A., Nasr, S.M., Shoukry, M., Spirulina platensis prevents hyperglycemia in rats by modulating gluconeogenesis and apoptosis via modification of oxidative stress and MAPK-pathways. Biomed Pharmacother 92 (2017), 1085–1094.
45. Fujimoto, M., Tsuneyama, K., Fujimoto, T., et al. Spirulina improves non-alcoholic steatohepatitis, visceral fat macrophage aggregation, and serum leptin in a mouse model of metabolic syndrome. Dig Liver Dis 44:9 (2012), 767–774.
46. Szulinska, M., Gibas-Dorna, M., Miller-Kasprzak, E., et al. Spirulina maxima improves insulin sensitivity, lipid profile, and total antioxidant status in obese patients with well-treated hypertension: a randomized double-blind placebo-controlled study. Eur Rev Med Pharmacol Sci 21:10 (2017), 2473–2481.
47. Gargouri, M., Magné, C., El Feki, A., Hyperglycemia, oxidative stress, liver damage and dysfunction in alloxan-induced diabetic rat are prevented by Spirulina supplementation. Nutr Res 36:11 (2016), 1255–1268.
48. Hua, P., Yu, Z., Xiong, Y., Liu, B., Zhao, L., Regulatory efficacy of Spirulina platensis protease hydrolyzate on lipid metabolism and gut microbiota in high-fat diet-fed rats. Int J Mol Sci, 19(12), 2018.
49. Iwata, K., Inayama, T., Kato, T., Effects of Spirulina platensis on plasma lipoprotein lipase activity in fructose-induced hyperlipidemic rats. J Nutr Sci Vitaminol (Tokyo) 36:2 (1990), 165–171.
50. Nagaoka, S., Shimizu, K., Kaneko, H., et al. A novel protein C-phycocyanin plays a crucial role in the hypocholesterolemic action of Spirulina platensis concentrate in rats. J Nutr 135:10 (2005), 2425–2430.
51. Mazokopakis, E.E., Starakis, I.K., Papadomanolaki, M.G., Mavroeidi, N.G., Ganotakis, E.S., The hypolipidaemic effects of Spirulina (Arthrospira platensis) supplementation in a Cretan population: a prospective study. J Sci Food Agric 94:3 (2014), 432–437.
52. Zeinalian, R., Farhangi, M.A., Shariat, A., Saghafi-Asl, M., The effects of Spirulina Platensis on anthropometric indices, appetite, lipid profile and serum vascular endothelial growth factor (VEGF) in obese individuals: a randomized double blinded placebo controlled trial. BMC Complement Altern Med, 17(1), 2017, 225.
53. Sáinz, N., Barrenetxe, J., Moreno-Aliaga, M.J., Martínez, J.A., Leptin resistance and diet-induced obesity: central and peripheral actions of leptin. Metabolism 64:1 (2015), 35–46.
54. Achari, A.E., Jain, S.K., Adiponectin, a therapeutic target for obesity, diabetes, and endothelial dysfunction. Int J Mol Sci, 18(6), 2017.
55. Vazquez-Velasco, M., Gonzalez-Torres, L., Mendez, M.T., et al. Glucomannan and Glucomannan plus Spirulina-enriched squid-surimi added to high saturated diet affect glycemia, plasma and adipose Leptin and adiponectin levels in growing FA/FA RATS. Nutr Hosp 32:6 (2015), 2718–2724.
56. Marles, R.J., Barrett, M.L., Barnes, J., et al. United States pharmacopeia safety evaluation of spirulina. Crit Rev Food Sci Nutr 51:7 (2011), 593–604.
57. Higgins, I., Parker, V., Keatinge, D., et al. Doing clinical research: the challenges and benefits. Contemp Nurse 35:2 (2010), 171–181.
58. Wadden, T.A., Bray, G.A., Handbook of obesity treatment. 2018, Guilford Publications.